Includes 8 Oral Presentations and Award of Best Clinical Abstract ARTARMON, Australia, Jan. 21, 2020 /PRNewswire/ -- Saluda Medical Pty Limited ("Saluda Medical") today announced that data from ...
The Evoke ® System is the First SCS System to Demonstrate Cost-Dominance at Two Years Post-Implant MINNEAPOLIS, Aug. 4, 2023 /PRNewswire/ -- Saluda Medical, Inc. ("Saluda Medical"), a global medical ...
The Evoke® SCS System is now covered by all major commercial payers and Medicare, providing broad patient access for this important therapy to over 200 million lives. 20 pain societies pledged their ...
ARTARMON, Australia, March 22, 2023 /PRNewswire/ -- Saluda Medical Pty Limited ("Saluda Medical"), a global medical device company revolutionizing the field of neuromodulation, today announced that ...
Presentations Included First Human Data on EVA(TM), Saluda's Automated SCS Programming Platform MINNEAPOLIS, Feb. 5, 2025 /PRNewswire/ -- Saluda Medical, Inc., a pioneer in the development and ...
MINNEAPOLIS, July 17, 2025 /PRNewswire/ -- Saluda Medical, Inc., a pioneer in the development and commercialization of a novel neuromodulation platform designed to transform the lives of patients with ...
MINNEAPOLIS, Aug. 4, 2023 /PRNewswire/ -- Saluda Medical, Inc. ("Saluda Medical"), a global medical device company revolutionizing the field of neuromodulation with an emerging portfolio of therapies ...